Targeting PD-1 or TIM3 allows the restoration of immune function in these cells, but the greatest impact on controlling tumour growth appears when both targets are treated simultaneously.18 In another murine model, this time of NSCLC, TIM3 was upregulated in the case of progression after an initial response to anti-PD-1 ICI. The gene discussed is HAVCR2; the disease is neoplasm.